Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
US10618960B2 · kind B2 · utility
4Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 14, 2016 |
| Grant date | Apr 14, 2020 |
| Priority date | — |
| Expiry date | Apr 10, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.